• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    National Securities initiated coverage on Genprex with a new price target

    1/26/21 7:48:53 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GNPX alert in real time by email
    National Securities initiated coverage of Genprex with a rating of Buy and set a new price target of $7.00
    Get the next $GNPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $GNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 4,500 shares, decreasing direct ownership by 20% to 17,971 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      7/1/25 5:52:13 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO and CFO Confer Ryan M. covered exercise/tax liability with 5,775 shares, decreasing direct ownership by 15% to 32,968 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      7/1/25 5:51:04 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Berger Mark Stanley covered exercise/tax liability with 585 shares, decreasing direct ownership by 3% to 22,471 units (SEC Form 4)

      4 - Genprex, Inc. (0001595248) (Issuer)

      2/19/25 8:01:36 PM ET
      $GNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care